Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213681 | 0.72 | MAPT (0.39) | MAPTTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3807641 | 0.71 | MAPT (0.39) | MAPTTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1447816 | 0.67 | MAPT (0.45) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL27372120 | 0.65 | MAPT (0.43) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL8692422 | 0.64 | MAPT (0.42) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL8060549 | 0.64 | MAPT (0.42) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL27313503 | 0.63 | MAPT (0.55) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL4655299 | 0.62 | MAPT (0.66) | MAPTTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL235799 | 0.62 | MAPT (0.41) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL10898596 | 0.61 | GAA (0.51) | MAPTTDP1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0278944-B1 | SUBSTITUTED 2,6-SUBSTITUTED PYRIDINE COMPOUNDS | Monsanto Company (US) | 1992-09-30 | — | — | EP | claimed |
| CN-113861181-B | Polysubstituted isothiazole derivative and preparation method thereof | 云南大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20070248594-A1 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | SCHERING CORPORATION | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248594-A1 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | CXCR1, CXCR2, CXCR5 | MAPT 4819/4885TDP1 3900/4885SMN1; SMN2 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.